The Rise Of Vector Therapies In Genetic Disorder Treatment: Pivotal Factor Influencing Viral And Non-Viral Vector Manufacturing Market Growth in 2025

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

Viral And Non-Viral Vector Manufacturing Market Size Growth Forecast: What to Expect by 2025?
In recent times, the market size for viral and non-viral vector manufacturing has seen a swift expansion. The projected growth shows an increase from $8.67 billion in 2024 to $10.3 billion in 2025, representing a compound annual growth rate (CAGR) of 18.8%. The exceptional growth during this historic period can be credited to the increasing occurrence of genetic disorders, biotech advancements, heightened investment in gene therapy research, rising consciousness of personalized medicine, and strong regulatory backing for the development of gene therapy.

How Will the Viral And Non-Viral Vector Manufacturing Market Size Evolve and Grow by 2029?
The market size of viral and non-viral vector manufacturing is predicted to experience a significant surge in the next few years. The market is estimated to reach $22.06 billion by 2029, with the compound annual growth rate (CAGR) clocking in at an impressive 21.0%. A boom in demand for gene therapies, broader applications in treating rare diseases, rising investment in biomanufacturing infrastructure, and an increased uptake in precision medicine are all contributors to this projected growth in the forecast period. Key trends in the said period include the creation of next-generation viral vectors, a heightened application of CRISPR or cas9 technology within vector manufacturing, the concentration on scalable and cost-effective manufacturing techniques, a surge in the use of non-viral vectors and with continual advancements in cell and gene therapy manufacturing technologies.

View the full report here:
https://www.thebusinessresearchcompany.com/report/viral-and-non-viral-vector-manufacturing-global-market-report

What Drivers Are Propelling the Growth of Viral And Non-Viral Vector Manufacturing Market Forward?
The growth of the viral and non-viral vector manufacturing markets is anticipated to be driven by the rising occurrence of genetic disorders. Genetic diseases, which arise from an alteration in the normal DNA sequence, are becoming increasingly common. Therapeutic genes are delivered to targeted cells using viral vectors, which helps replace or supplement the faulty genes responsible for these genetic diseases. In ex vivo gene therapy applications, non-viral vectors are frequently used to genetically modify cells outside the body before reintroducing them to the patient. The International Diabetes Federation, a Belgium-based organization, reported in June 2022 that the global prevalence of diabetes has risen to 10.5%. According to their findings, over 44.7% of people remain undiagnosed, and it is projected that by 2045, about 783 million adults, or one out of every eight people, will have diabetes. Consequently, the escalating prevalence of genetic disorders propels the expansion of the viral and non-viral vector manufacturing market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12570&type=smp

Which Emerging Trends Are Transforming the Viral And Non-Viral Vector Manufacturing Market in 2025?
The area of viral and non-viral vector manufacturing markets is experiencing substantial growth thanks to breakthroughs in technology. To maintain their market standing, leading companies in these markets are focusing on the creation of cutting-edge solutions. For example, in August 2022, Merck KGaA, a prominent science and technology company based in Germany, introduced the VirusExpress 293 Adeno-Associated Virus (AAV) Production Platform. This makes it one of the pioneering contract development and manufacturing organizations and technology innovators to provide a comprehensive viral vector manufacturing suite, including features like AAV, Lentiviral, CDMO, CTO, and process development. Such an advanced platform allows biopharmaceutical companies to minimize both the time and cost involved in process development, while hastening the transition to clinical manufacturing.

What Are the Key Segments in the Viral And Non-Viral Vector Manufacturing Market?
The viral and non-viral vector manufacturing market covered in this report is segmented -

1) By Vector Type: Viral Vector, Non-Viral Vector
2) By Disease: Cancer, Genetic Disease, Infectious Disease, Cardiovascular Disease, Other Diseases
3) By Application: Gene Therapy, Vaccinology, Cell Therapy, Other Applications

Subsegments:
1) By Viral Vector: Adenoviral Vectors, Lentiviral Vectors, AAV (Adeno-Associated Virus) Vectors, Retroviral Vectors, Other Viral Vectors
2) By Non-Viral Vector: Plasmid DNA, Lipid-Based Vectors, Nanoparticles, Electroporation-Based Vectors, Other Non-Viral Vectors

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=12570&type=smp

Who Are the Key Players Shaping the Viral And Non-Viral Vector Manufacturing Market's Competitive Landscape?
Major companies operating in the viral and non-viral vector manufacturing market include Novartis AG, Thermo Fisher Scientific Inc., Merck KGaA, FUJIFILM Holdings Corporation, Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Lonza Group AG, WuXi AppTec Co Ltd., Catalent Inc., Sartorius AG, Charles River Laboratories Inc., Sarepta Therapeutics Inc., GenScript ProBio Co. Ltd., TAKARA BIO Inc., Oxford BioMedica plc, Beam Therapeutics Inc., Intellia Therapeutics Inc., MaxCyte Inc., Voyager Therapeutics Inc., Genethon, MeiraGTx Holdings plc, Evox Therapeutics Ltd., Entos Pharmaceuticals Inc., LogicBio Therapeutics Inc., bluebird bio Inc., 4D Molecular Therapeutics Inc., Precision NanoSystems Inc., GenSight Biologics S.A., Abeona Therapeutics Inc., Generation Bio Co.

What Geographic Markets Are Powering Growth in the Viral And Non-Viral Vector Manufacturing Market?
North America was the largest region in the viral and non-viral vector manufacturing market in 2024. The regions covered in the viral and non-viral vector manufacturing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12570

This Report Supports:
1. Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2. Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3. Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4. Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 7882 955267,
Asia: +91 88972 63534,
Americas: +1 310-496-7795 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.